Cellebrite DI Ltd. (CLBT) Stock Price & How to Invest

Cellebrite DI Ltd. sells the digital-intelligence toolchain used in criminal investigations. Its access products (the Inseyets line, successor to the UFED hardware kits) unlock and extract data from mobile devices, Guardian handles cloud-based evidence review and sharing across agencies, Pathfinder and the newer AI products correlate evidence across seized devices, and Endpoint Inspector covers computers and corporate endpoints. Customers are police forces, national security agencies, prosecutors and, increasingly, corporate investigations and incident-response teams. The company is headquartered in Petah Tikva, Israel, listed on Nasdaq after a 2021 SPAC merger, and files as a foreign private issuer on Form 20-F. In late 2025 it closed the ~$170 million acquisition of Corellium, whose virtualized ARM device platform is used for mobile app security research, and paired that deal with a restructuring.

The investment picture is a subscription software story wearing a government-contracting jacket, and 2026 has tested it. Annual recurring revenue reached about $508 million in the second quarter of 2026, up 21% year over year, and quarterly revenue grew about 16% to roughly $131 million, with EPS of $0.11 in line with the consensus. But management lowered its 2026 outlook alongside those results, attributing quarterly volatility to the shift toward a consumption-based cloud platform and to longer government procurement cycles, and Shiv Ramji replaced Tom Hogan as CEO. In September the board approved a reorganization that would put a new US corporation at the top of the group, expected in the first half of 2027 subject to shareholder and regulatory approvals. The shares have fallen about 39% in 2026 and 26% over the past three months, to about $10.91 on October 16. Trailing revenue is about $514 million at an 83% gross margin, free cash flow over the last twelve months is roughly $125 million, and the balance sheet holds about $443 million of cash against roughly $23 million of debt, so at a ~$2.7 billion market value the enterprise trades near 4.5x trailing revenue. What that multiple pays for is renewal-heavy demand from agencies that rarely switch vendors; what it exposes is lumpy public-sector purchasing, an ongoing arms race against Apple and Google device security, and the reputational risk of tools sold to states that misuse them.

The 2026 guidance cut shows how quickly this can bite: revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. Access capability is a moving target: every iOS and Android hardening release can strip a supported extraction method, and Cellebrite must keep re-earning it, which is why its spring 2026 update advertising iPhone 17 and iOS 26 support was itself news. The reputational exposure is real and recurring, from Amnesty International's 2024 report on Cellebrite tools used against Serbian activists (after which the company stopped selling there) to political scrutiny of its expanded U.S. immigration-enforcement contracts. Competition is well capitalized, with Magnet Forensics and GrayKey combined under private ownership. As an Israel-domiciled foreign private issuer, Cellebrite reports on a 20-F with semiannual rather than quarterly filing obligations, carries regional geopolitical risk, and its GAAP results swing on warrant revaluation and share-based compensation. Leadership transition and the planned US redomicile add execution risk through 2027, and full-year 2026 revenue consensus of about $557 million now sits below the $565 million to $571 million range the company guided to earlier in the year.

7 analysts publish price targets on CLBT, averaging $15.36 against a $12.26 price as of November 2026, or +25.3%. The published targets run from $12.50 to $20.00, a moderate spread, and the ratings split 8 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CLBT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cellebrite DI Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. ARR compounding on the subscription shift. Cellebrite reached about $508 million of ARR in the second quarter of 2026, up 21% year over year, even as reported revenue growth slowed to about 16%. The most optimistic published target, $20.00, assumes this works close to its best case.

The case against. The 2026 guidance cut shows how quickly this can bite: revenue depends on government budgets, so procurement freezes, continuing resolutions and election-cycle delays can push deals across quarters with no change in demand. The most pessimistic target, $12.50, is roughly what CLBT is worth if this bites instead.

Read the full bull and bear case on CLBT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Cellebrite DI Ltd. (CLBT) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cellebrite DI Ltd.'s investor relations page or your broker.

• Revenue (TTM): ~$514 million
• Revenue growth (Q2 2026, YoY): ~16%
• ARR (Q2 2026): ~$508 million, up ~21% year over year
• Gross / operating margin (TTM): ~83% / ~5%
• Net income (TTM): ~$58 million
• P/E (trailing / forward): ~47x / ~17x
• Free cash flow (TTM): ~$125 million
• Market cap and net cash: ~$2.7 billion; ~$443 million cash vs ~$23 million debt

At about $10.91 on October 16, 2026, Cellebrite trades near 4.5x trailing revenue on enterprise value and about 17x forward earnings, well below the ~7x revenue multiple it carried in mid-2026 before the guidance cut. Consensus for 2026 is about $557 million of revenue and $0.55 of EPS, rising to roughly $641 million and $0.65 in 2027. Third-quarter results are expected around November 11, 2026, with consensus near $0.16 EPS on about $146 million of revenue; the seven covering analysts carry a mean target near $15.

Other names that sit close to CLBT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

There are three common ways to get CLBT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CLBT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CLBT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Cellebrite is a high-margin, cash-generative software franchise in digital investigations whose ARR still grows about 21% a year, but a lowered 2026 outlook, a new CEO and a planned move to US domicile have reset the stock to roughly 4.5x trailing revenue, in a business whose customers are governments and whose headlines are frequently uncomfortable.

Whether CLBT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CLBT a buy or a sell?, and where the stock could go from here in the CLBT stock forecast.

For income investors, whether CLBT pays a dividend and how the payout looks is covered in does CLBT pay a dividend? And to weigh CLBT against a peer, read the full side-by-side comparisons: CLBT vs MSI and CLBT vs PLTR.